|
1
|
Woolcott RJ, Henry RJ and Houghton CR:
Malignant melanoma of the vulva. Australian experience. J Reprod
Med. 33:699–702. 1988.PubMed/NCBI
|
|
2
|
Ragnarsson-Olding BK: Primary malignant
melanoma of the vulva - an aggressive tumor for modeling the
genesis of non-UV light-associated melanomas. Acta Oncol.
43:421–435. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bradgate MG, Rollason TP, McConkey CC, et
al: Malignant melanoma of the vulva: a clinicopathological study of
50 women. Br J Obstet Gynaecol. 97:124–133. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blessing K, Kernohan NM and Park KG:
Subungual malignant melanoma: clinicopathological features of 100
cases. Histopathology. 19:425–429. 1999. View Article : Google Scholar
|
|
5
|
Ragnarsson-Olding BK, Kanter-Lewensohn LR,
Lagerlof B, et al: Malignant melanoma of the vulva in a nationwide,
25-year study of 219 Swedish females: clinical observations and
histopathologic features. Cancer. 86:1273–1284. 1999.
|
|
6
|
Ragnarsson-Olding BK, Nilsson BR,
Kanter-Lewensohn LR, et al: Malignant melanoma of the vulva in a
nationwide, 25-year study of 219 Swedish females: predictors of
survival. Cancer. 86:1285–1293. 1999.
|
|
7
|
Ragnarsson-Olding B, Platz A, Olding L, et
al: p53 protein expression and TP53 mutations in malignant
melanomas of sun-sheltered mucosal membranes versus chronically
sun-exposed skin. Melanoma Res. 14:395–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Irvin WP Jr, Legallo RL, Stoler MH, et al:
Vulvar melanoma: a retrospective analysis and literature review.
Gynecol Oncol. 83:457–465. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verschraegen CF, Benjapibal M,
Supakarapongkul W, et al: Vulvar melanoma at the M.D. Anderson
Cancer Center: 25 years later. Int J Gynecol Cancer. 11:359–364.
2001.PubMed/NCBI
|
|
10
|
Sugiama VE, Chan JK, Shin JY, et al:
Vulvar melanoma: a multivariable analysis of 644 patients. Obstet
Gynecol. 110:296–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu DN, Yu GP and McCormick SA:
Population-based incidence of vulvar and vaginal melanoma in
various races and ethnic groups with comparisons to other
site-specific melanomas. Melanoma Res. 20:153–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mert I, Semaan A, Winer I, et al:
Vulvar/Vaginal melanoma: an updated surveillance epidemiology and
end results database review, comparison with cutaneous melanoma and
significance of racial disparities. Int J Gynecol Cancer.
23:1118–1125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Omholt K, Grafstrom E, Kanter-Lewensohn L,
et al: KIT pathway alterations in mucosal melanomas of the vulva
and other sites. Clin Cancer Res. 17:3933–3942. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schoenewolf NL, Bull C, Belloni B, et al:
Sinonasal, genital and acrolentiginous melanomas show distinct
characteristics of KIT expression and mutations. Eur J Cancer.
48:1842–1852. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiveskog S, Ragnarsson-Olding B, Platz A,
et al: N-ras mutations are common in melanomas from sun-exposed
skin of humans but rare in mucosal membranes or unexposed skin. J
Invest Dermatol. 111:757–761. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedman RJ, Kopf AW and Jones WB:
Malignant melanoma in association with lichen sclerosus on the
vulva of a 14-year-old. Am J Dermatopathol. 6(Suppl): 253–256.
1984.PubMed/NCBI
|
|
17
|
Egan CA, Bradley RR, Logsdon VK, et al:
Vulvar melanoma in childhood. Arch Dermatol. 133:345–348. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carlson JA, Mu XC, Slominski A, et al:
Melanocytic proliferations associated with lichen sclerosus. Arch
Dermatol. 138:77–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hassanein AM, Mrstik ME, Hardt NS, et al:
Malignant melanoma associated with lichen sclerosus in the vulva of
a 10-year-old. Pediatr Dermatol. 21:473–476. 2004.PubMed/NCBI
|
|
20
|
Rosamilia LL, Schwartz JL, Lowe L, et al:
Vulvar melanoma in a 10-year-old girl in association with lichen
sclerosus. J Am Acad Dermatol. 54:S52–S53. 2006.PubMed/NCBI
|
|
21
|
Powell JJ and Wojnarowska F: Lichen
sclerosus. Lancet. 353:1777–1783. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scurry J: Does lichen sclerosus play a
central role in the pathogenesis of human papillomavirus negative
vulvar squamous cell carcinoma? The itch-scratch-lichen sclerosus
hypothesis. Int J Gynecol Cancer. 9:89–97. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Smith YR and Haefner HK: Vulvar lichen
sclerosus: pathophysiology and treatment. Am J Clin Dermatol.
5:105–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
El Shabrawi-Caelen L, Soyer HP, Schaeppi
H, et al: Genital lentigines and melanocytic nevi with superimposed
lichen sclerosus: a diagnostic challenge. J Am Acad Dermatol.
50:690–694. 2004.PubMed/NCBI
|
|
25
|
Breslow A: Thickness, cross-sectional
areas and depth of invasion in the prognosis of cutaneous melanoma.
Ann Surg. 172:902–908. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chung AF, Woodruff JM and Lewis JL Jr:
Malignant melanoma of the vulva: a report of 44 cases. Obstet
Gynecol. 45:638–646. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Podratz KC, Gaffey TA, Symmonds RE, et al:
Melanoma of the vulva: an update. Gynecol Oncol. 16:153–168. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim CJ, Reintgen DS and Balch CM: The new
melanoma staging system. Cancer Control. 9:9–15. 2002.
|
|
29
|
Zambo K, Szabo Z, Schmidt E, et al: Is the
clinical staging system a good choice in the staging of vulvar
malignancies? Eur J Nucl Med Mol Imaging. 34:1878–1879. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tcheung WJ, Selim MA, Herndon JE 2nd, et
al: Clinicopathologic study of 85 cases of melanoma of the female
genitalia. J Am Acad Dermatol. 67:598–605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scheistroen M, Trope C, Koern J, et al:
Malignant melanoma of the vulva. Evaluation of prognostic factors
with emphasis on DNA ploidy in 75 patients. Cancer. 75:72–80. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trimble EL, Lewis JL Jr, Williams LL, et
al: Management of vulvar melanoma. Gynecol Oncol. 45:254–258. 1992.
View Article : Google Scholar
|
|
33
|
Tasseron EW, van der Esch EP, Hart AA, et
al: A clinicopathological study of 30 melanomas of the vulva.
Gynecol Oncol. 46:170–175. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Piura B, Egan M, Lopes A, et al: Malignant
melanoma of the vulva: a clinicopathologic study of 18 cases. J
Surg Oncol. 50:234–240. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ragnarsson-Olding B, Johansson H, Rutqvist
LE, et al: Malignant melanoma of the vulva and vagina. Trends in
incidence, age distribution, and long-term survival among 245
consecutive cases in Sweden 1960–1984. Cancer. 71:1893–1897.
1993.PubMed/NCBI
|
|
36
|
Look KY, Reisinger M, Stehman FB, et al:
Blood transfusion and the risk of recurrence in squamous carcinoma
of the vulva. Am J Obstet Gynecol. 168:1718–1723. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Phillips GL, Bundy BN, Okagaki T, et al:
Malignant melanoma of the vulva treated by radical hemivulvectomy.
A prospective study of the Gynecologic Oncology Group. Cancer.
73:2626–2632. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dunton CJ, Kautzky M and Hanau C:
Malignant melanoma of the vulva: a review. Obstet Gynecol Surv.
50:739–746. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raber G, Mempel V, Jackisch C, et al:
Malignant melanoma of the vulva. Report of 89 patients. Cancer.
78:2353–2358. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Trimble EL: Melanomas of the vulva and
vagina. Oncology (Williston Park). 10:1017–1024. 1996.PubMed/NCBI
|
|
41
|
Scheistroen M, Trope C, Kaern J, et al:
Malignant melanoma of the vulva FIGO stage I: evaluation of
prognostic factors in 43 patients with emphasis on DNA ploidy and
surgical treatment. Gynecol Oncol. 61:253–258. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Strauss BS: Silent and multiple mutations
in p53 and the question of the hypermutability of tumors.
Carcinogenesis. 18:1445–1452. 1997.PubMed/NCBI
|
|
43
|
De Matos P, Tyler D and Seigler HF:
Mucosal melanoma of the female genitalia: a clinicopathologic study
of forty-three cases at Duke University Medical Center. Surgery.
124:38–48. 1998.PubMed/NCBI
|
|
44
|
Larsson KB, Shaw HM, Thompson JF, et al:
Primary mucosal and glans penis melanomas: the Sydney Melanoma Unit
experience. Aust N Z J Surg. 69:121–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Creasman WT, Phillips JL and Menck HR: A
survey of hospital management practices for vulvar melanoma. J Am
Coll Surg. 188:670–675. 1999.PubMed/NCBI
|
|
46
|
Raspagliesi F, Ditto A, Paladini D, et al:
Prognostic indicators in melanoma of the vulva. Ann Surg Oncol.
7:738–742. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ragnarsson-Olding BK, Karsberg S, Platz A,
et al: Mutations in the TP53 gene in human malignant melanomas
derived from sun-exposed skin and unexposed mucosal membranes.
Melanoma Res. 12:453–463. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
De Hullu JA, Hollema H, Hoekstra HJ, et
al: Vulvar melanoma: is there a role for sentinel lymph node
biopsy? Cancer. 94:486–491. 2002.
|
|
49
|
Finan MA and Barre G: Bartholin’s gland
carcinoma, malignant melanoma and other rare tumours of the vulva.
Best Pract Res Clin Obstet Gynaecol. 17:609–633. 2003.
|
|
50
|
Harting MS and Kim KB: Biochemotherapy in
patients with advanced vulvovaginal mucosal melanoma. Melanoma Res.
14:517–520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wechter ME, Gruber SB, Haefner HK, et al:
Vulvar melanoma: a report of 20 cases and review of the literature.
J Am Acad Dermatol. 50:554–562. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Edwards RH, Ward MR, Wu H, et al: Absence
of BRAF mutations in UV-protected mucosal melanomas. J Med Genet.
41:270–272. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dahlgren L, Schedvins K, Kanter-Lewensohn
L, et al: Human papilloma virus (HPV) is rarely detected in
malignant melanomas of sun sheltered mucosal membranes. Acta Oncol.
44:694–699. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Stang A, Streller B, Eisinger B, et al:
Population-based incidence rates of malignant melanoma of the vulva
in Germany. Gynecol Oncol. 96:216–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rouzier R, Haddad B, Atallah D, et al:
Surgery for vulvar cancer. Clin Obstet Gynecol. 48:869–878. 2005.
View Article : Google Scholar
|
|
56
|
Lundberg R, Brytting M, Dahlgren L, et al:
Human herpes virus DNA is rarely detected in non-UV
light-associated primary malignant melanomas of mucous membranes.
Anticancer Res. 26:3627–3631. 2006.PubMed/NCBI
|
|
57
|
Dhar KK, Das N, Brinkman DA, et al:
Utility of sentinel node biopsy in vulvar and vaginal melanoma:
report of two cases and review of the literature. Int J Gynecol
Cancer. 17:720–723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Giraud G, Ramqvist T, Ragnarsson-Olding B,
et al: DNA from BK virus and JC virus and from KI, WU, and MC
polyomaviruses as well as from simian virus 40 is not detected in
non-UV-light-associated primary malignant melanomas of mucous
membranes. J Clin Microbiol. 46:3595–3598. 2008. View Article : Google Scholar
|
|
59
|
De Simone P, Silipo V, Buccini P, et al:
Vulvar melanoma: a report of 10 cases and review of the literature.
Melanoma Res. 18:127–133. 2008.PubMed/NCBI
|
|
60
|
Moan J, Porojnicu AC, Dahlback A, et al:
Where the sun does not shine: is sunshine protective against
melanoma of the vulva? J Photochem Photobiol B. 101:179–183. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Trifiro G, Travaini LL, Sanvito F, et al:
Sentinel node detection by lymphoscintigraphy and sentinel lymph
node biopsy in vulvar melanoma. Eur J Nucl Med Mol Imaging.
37:736–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Terlou A, Blok LJ, Helmerhorst TJ, et al:
Premalignant epithelial disorders of the vulva: squamous vulvar
intraepithelial neoplasia, vulvar Paget’s disease and melanoma in
situ. Acta Obstet Gynecol Scand. 89:741–748. 2010.
|
|
63
|
Baiocchi G, Duprat JP, Neves RI, et al:
Vulvar melanoma: report on eleven cases and review of the
literature. Sao Paulo Med J. 128:38–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ragnarsson-Olding BK: Spatial density of
primary malignant melanoma in sun-shielded body sites: a potential
guide to melanoma genesis. Acta Oncol. 50:323–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar
|
|
66
|
Postow MA and Carvajal RD: Therapeutic
implications of KIT in melanoma. Cancer J. 18:137–141. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Markman B, Dienstmann R and Tabernero J:
Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget.
1:530–543. 2010.PubMed/NCBI
|
|
68
|
De Luca A, Maiello MR, D’Alessio A, et al:
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in
cancer pathogenesis and implications for therapeutic approaches.
Expert Opin Ther Targets. 16(Suppl 2): S17–S27. 2012.PubMed/NCBI
|
|
69
|
Mehnert JM and Kluger HM: Driver mutations
in melanoma: lessons learned from bench-to-bedside studies. Curr
Oncol Rep. 14:449–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huang Q, Huang H, Wan T, Deng T and Liu J:
Clinical outcome of 31 patients with primary malignant melanoma of
the vagina. J Gynecol Oncol. 24:330–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kornberg R, Harris M and Ackerman AB:
Epidermotropically metastatic malignant melanoma. Differentiating
malignant melanoma metastatic to the epidermis from malignant
melanoma primary in the epidermis. Arch Dermatol. 114:67–69. 1978.
View Article : Google Scholar
|
|
72
|
Jaramillo BA, Ganjei P, Averette HE, et
al: Malignant melanoma of the vulva. Obstet Gynecol. 66:398–401.
1985.PubMed/NCBI
|
|
73
|
Beller U, Demopoulos RI and Beckman EM:
Vulvovaginal melanoma. A clinicopathologic study. J Reprod Med.
31:315–319. 1986.PubMed/NCBI
|
|
74
|
Kirkwood JM, Strawderman MH, Ernstoff MS,
et al: Interferon alfa-2b adjuvant therapy of high-risk resected
cutaneous melanoma: the Eastern Cooperative Oncology Group Trial
EST 1684. J Clin Oncol. 14:7–17. 1996.PubMed/NCBI
|
|
75
|
Kirkwood JM, Ibrahim J, Lawson DH, et al:
High-dose interferon alfa-2b does not diminish antibody response to
GM2 vaccination in patients with resected melanoma: results of the
Multicenter Eastern Cooperative Oncology Group Phase II Trial
E2696. J Clin Oncol. 19:1430–1436. 2001.
|
|
76
|
Gray RJ, Pockaj BA and Kirkwood JM: An
update on adjuvant interferon for melanoma. Cancer Control.
9:16–21. 2002.PubMed/NCBI
|
|
77
|
Dunton CJ and Berd D: Vulvar melanoma,
biologically different from other cutaneous melanomas. Lancet.
354:2013–2014. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Handolias D, Salemi R, Murray W, et al:
Mutations in KIT occur at low frequency in melanomas arising from
anatomical sites associated with chronic and intermittent sun
exposure. Pigment Cell Melanoma Res. 23:210–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
